KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBIT: 2014-2024

Historic EBIT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Dec 2024 value amounting to -$466.6 million.

  • CRISPR Therapeutics AG's EBIT fell 19.91% to -$132.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$574.4 million, marking a year-over-year decrease of 72.81%. This contributed to the annual value of -$466.6 million for FY2024, which is 109.66% down from last year.
  • CRISPR Therapeutics AG's EBIT amounted to -$466.6 million in FY2024, which was down 109.66% from -$222.5 million recorded in FY2023.
  • CRISPR Therapeutics AG's 5-year EBIT high stood at $373.5 million for FY2021, and its period low was -$673.2 million during FY2022.
  • Over the past 3 years, CRISPR Therapeutics AG's median EBIT value was -$466.6 million (recorded in 2024), while the average stood at -$454.1 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's EBIT crashed by 858.31% in 2020 and then skyrocketed by 205.39% in 2021.
  • Over the past 5 years, CRISPR Therapeutics AG's EBIT (Yearly) stood at -$354.4 million in 2020, then surged by 205.39% to $373.5 million in 2021, then crashed by 280.22% to -$673.2 million in 2022, then skyrocketed by 66.94% to -$222.5 million in 2023, then plummeted by 109.66% to -$466.6 million in 2024.